Figure 4.
CTLA-4 ligand uptake reveals defects in patients with CTLA-4 deficiency. (A) Expression of Foxp3 and total CTLA-4 (BN13) on unstimulated CD45RA− memory CD4 T cells were compared between a ligand-binding mutant (P137R) and healthy control. CTLA-4 MFI in Foxp3+ and Foxp3− populations is shown in large font. Percentages are shown in quadrants. (B) Impaired ligand uptake by CTLA-4–deficient patient. CD4 T cells were stimulated with CD3/CD28 beads and gated on Foxp3+ cells. Total CTLA-4 staining (C19 antibody) is plotted against ligand uptake (CD80-Ig). Changes in slope reflect alterations in ligand uptake efficiency and are overlaid in control plot. CD80-Ig MFI (top right) and CTLA-4 MFI (bottom right) are shown in large font. (C) Comparison of the slope of the line of best fit from the data in panel B.

CTLA-4 ligand uptake reveals defects in patients with CTLA-4 deficiency. (A) Expression of Foxp3 and total CTLA-4 (BN13) on unstimulated CD45RA− memory CD4 T cells were compared between a ligand-binding mutant (P137R) and healthy control. CTLA-4 MFI in Foxp3+ and Foxp3− populations is shown in large font. Percentages are shown in quadrants. (B) Impaired ligand uptake by CTLA-4–deficient patient. CD4 T cells were stimulated with CD3/CD28 beads and gated on Foxp3+ cells. Total CTLA-4 staining (C19 antibody) is plotted against ligand uptake (CD80-Ig). Changes in slope reflect alterations in ligand uptake efficiency and are overlaid in control plot. CD80-Ig MFI (top right) and CTLA-4 MFI (bottom right) are shown in large font. (C) Comparison of the slope of the line of best fit from the data in panel B.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal